Breast Hypertrophy Induced by Ombitasvir/Paritaprevir/Ritonavir and Ribavirina

Breast J. 2016 Nov;22(6):708-709. doi: 10.1111/tbj.12656. Epub 2016 Aug 4.

Authors

Affiliations

¹ Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences, "Luigi Sacco" University Hospital, Università di Milano, Milan, Italy.
² Units of Infectious Diseases, "Luigi Sacco" University Hospital, Università di Milano, Milan, Italy.
³ Scientific Direction, IRCCS Foundation Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
⁴ Scientific Institute, IRCCS E. Medea, Lecco, Italy.
⁵ Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences, Consiglio Nazionale delle Ricerche, Institute of Neuroscience, University Hospital "Luigi Sacco", Università di Milano, Milan, Italy.

PMID: 27488453
DOI: 10.1111/tbj.12656

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Anilides / adverse effects
Anilides / therapeutic use
Antiviral Agents / adverse effects*
Antiviral Agents / therapeutic use
Breast Diseases / chemically induced*
Carbamates / adverse effects
Carbamates / therapeutic use
Cyclopropanes
Drug Therapy, Combination / adverse effects
Female
Hepatitis C / drug therapy
Humans
Hypertrophy / chemically induced
Lactams, Macrocyclic
Macrocyclic Compounds / adverse effects
Macrocyclic Compounds / therapeutic use
Middle Aged
Proline / analogs & derivatives
Ribavirin / adverse effects
Ribavirin / therapeutic use
Ritonavir / adverse effects
Ritonavir / therapeutic use
Sulfonamides
Valine

Substances

Anilides
Antiviral Agents
Carbamates
Cyclopropanes
Lactams, Macrocyclic
Macrocyclic Compounds
Sulfonamides
ombitasvir
Ribavirin
Proline
Valine
Ritonavir
paritaprevir